These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35296412)

  • 21. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
    Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
    AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.
    Kirkwood-Johnson L; Katayama N; Marikawa Y
    Toxicol Sci; 2021 Nov; 184(2):191-203. PubMed ID: 34515794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
    Mesplède T; Wainberg MA
    Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
    Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
    Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
    BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.
    Le X; Guo X; Sun J; Liu L; Shen Y; Wang J; Qi T; Wang Z; Tang Y; Song W; Yin L; Zhang L; Zhang R; Chen J
    Int J Infect Dis; 2022 Mar; 116():147-150. PubMed ID: 34999246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
    Rolle CP; Nguyen V; Hinestrosa F; DeJesus E
    AIDS Res Ther; 2021 May; 18(1):26. PubMed ID: 33941212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery.
    Maturavongsadit P; Paravyan G; Kovarova M; Garcia JV; Benhabbour SR
    Int J Pharm X; 2021 Dec; 3():100068. PubMed ID: 33392498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
    Ndashimye E; Arts EJ
    Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
    AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.